On November 2, 2020 Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immune modulators and precision therapies for solid tumor cancers, reported the upcoming virtual poster presentation of the first preclinical data from its anti-CCR8 antibody, FPA157 program, at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 35th Anniversary Annual Meeting being held from November 9-14, 2020 (Press release, Five Prime Therapeutics, NOV 2, 2020, View Source [SID1234569697]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Late-breaker Virtual Poster Presentation and Q&A Details:

Title: Development of FPA157, an anti-CCR8 depleting antibody engineered to preferentially eliminate tumor-infiltrating T regulatory cells

Poster Number: 861

Live Q&A Sessions: November 11, 2020 from 5:15-5:45 pm EST and November 13, 2020 from 4:40-5:10 EST

Author and Q&A Presenter: Edwina Naik, PhD, Associate Director, Immuno-Oncology Research

About FPA157

FPA157 is an antibody-dependent cell-mediated cytotoxicity (ADCC)-enhanced monoclonal antibody targeting CCR8 that is designed to deplete the T regulatory cell (Treg) population in the tumor microenvironment. Tregs inhibit anti-tumoral immune responses and act through multiple suppressive mechanisms.1,2 FPA157 is part of the Five Prime immuno-oncology antibody pipeline and is undergoing IND-enabling studies.